The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmaceutical CDMO Services Market Research Report 2024
Synopsis
A Contract DEevelopment and Manufacturing Organization (SDMO), is an organization that serves the pharmaceutical industry and provides clients with comprehensive services from drug development though manufacture.
The global Pharmaceutical CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CDMO Services.
Report Scope
The Pharmaceutical CDMO Services market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmaceutical CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm AB
AMRI Global
Patheon N.V.
Aenova Group
Catalent, Inc.
Amatsigroup
WuXi AppTec Group
Strides Pharma Science Limited
Piramal Pharma Solutions
Siegfried Ltd
Fareva Group
FAMAR Health Care Services
Segment by Type
Drug Substance Development and Manufacturing
Specialized Services
Lab-based Services
Segment by Application
Innovative Medicine
Patented Drug
Patent Expired Drug
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical CDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A Contract DEevelopment and Manufacturing Organization (SDMO), is an organization that serves the pharmaceutical industry and provides clients with comprehensive services from drug development though manufacture.
The global Pharmaceutical CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CDMO Services.
Report Scope
The Pharmaceutical CDMO Services market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmaceutical CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recipharm AB
AMRI Global
Patheon N.V.
Aenova Group
Catalent, Inc.
Amatsigroup
WuXi AppTec Group
Strides Pharma Science Limited
Piramal Pharma Solutions
Siegfried Ltd
Fareva Group
FAMAR Health Care Services
Segment by Type
Drug Substance Development and Manufacturing
Specialized Services
Lab-based Services
Segment by Application
Innovative Medicine
Patented Drug
Patent Expired Drug
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical CDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Services Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Drug Substance Development and Manufacturing
1.2.3 Specialized Services
1.2.4 Lab-based Services
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Services Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Innovative Medicine
1.3.3 Patented Drug
1.3.4 Patent Expired Drug
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Services Market Perspective (2019-2030)
2.2 Pharmaceutical CDMO Services Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Services Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmaceutical CDMO Services Historic Market Size by Region (2019-2024)
2.2.3 Pharmaceutical CDMO Services Forecasted Market Size by Region (2025-2030)
2.3 Pharmaceutical CDMO Services Market Dynamics
2.3.1 Pharmaceutical CDMO Services Industry Trends
2.3.2 Pharmaceutical CDMO Services Market Drivers
2.3.3 Pharmaceutical CDMO Services Market Challenges
2.3.4 Pharmaceutical CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Services Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Pharmaceutical CDMO Services Revenue Market Share by Players (2019-2024)
3.2 Global Pharmaceutical CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CDMO Services Revenue
3.4 Global Pharmaceutical CDMO Services Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Services Revenue in 2023
3.5 Pharmaceutical CDMO Services Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CDMO Services Product Solution and Service
3.7 Date of Enter into Pharmaceutical CDMO Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Services Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Services Historic Market Size by Type (2019-2024)
4.2 Global Pharmaceutical CDMO Services Forecasted Market Size by Type (2025-2030)
5 Pharmaceutical CDMO Services Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Services Historic Market Size by Application (2019-2024)
5.2 Global Pharmaceutical CDMO Services Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pharmaceutical CDMO Services Market Size (2019-2030)
6.2 North America Pharmaceutical CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmaceutical CDMO Services Market Size by Country (2019-2024)
6.4 North America Pharmaceutical CDMO Services Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Services Market Size (2019-2030)
7.2 Europe Pharmaceutical CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmaceutical CDMO Services Market Size by Country (2019-2024)
7.4 Europe Pharmaceutical CDMO Services Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Services Market Size (2019-2030)
8.2 Asia-Pacific Pharmaceutical CDMO Services Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmaceutical CDMO Services Market Size by Region (2019-2024)
8.4 Asia-Pacific Pharmaceutical CDMO Services Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Services Market Size (2019-2030)
9.2 Latin America Pharmaceutical CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmaceutical CDMO Services Market Size by Country (2019-2024)
9.4 Latin America Pharmaceutical CDMO Services Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Services Market Size (2019-2030)
10.2 Middle East & Africa Pharmaceutical CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmaceutical CDMO Services Market Size by Country (2019-2024)
10.4 Middle East & Africa Pharmaceutical CDMO Services Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm AB
11.1.1 Recipharm AB Company Detail
11.1.2 Recipharm AB Business Overview
11.1.3 Recipharm AB Pharmaceutical CDMO Services Introduction
11.1.4 Recipharm AB Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.1.5 Recipharm AB Recent Development
11.2 AMRI Global
11.2.1 AMRI Global Company Detail
11.2.2 AMRI Global Business Overview
11.2.3 AMRI Global Pharmaceutical CDMO Services Introduction
11.2.4 AMRI Global Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.2.5 AMRI Global Recent Development
11.3 Patheon N.V.
11.3.1 Patheon N.V. Company Detail
11.3.2 Patheon N.V. Business Overview
11.3.3 Patheon N.V. Pharmaceutical CDMO Services Introduction
11.3.4 Patheon N.V. Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.3.5 Patheon N.V. Recent Development
11.4 Aenova Group
11.4.1 Aenova Group Company Detail
11.4.2 Aenova Group Business Overview
11.4.3 Aenova Group Pharmaceutical CDMO Services Introduction
11.4.4 Aenova Group Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.4.5 Aenova Group Recent Development
11.5 Catalent, Inc.
11.5.1 Catalent, Inc. Company Detail
11.5.2 Catalent, Inc. Business Overview
11.5.3 Catalent, Inc. Pharmaceutical CDMO Services Introduction
11.5.4 Catalent, Inc. Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.5.5 Catalent, Inc. Recent Development
11.6 Amatsigroup
11.6.1 Amatsigroup Company Detail
11.6.2 Amatsigroup Business Overview
11.6.3 Amatsigroup Pharmaceutical CDMO Services Introduction
11.6.4 Amatsigroup Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.6.5 Amatsigroup Recent Development
11.7 WuXi AppTec Group
11.7.1 WuXi AppTec Group Company Detail
11.7.2 WuXi AppTec Group Business Overview
11.7.3 WuXi AppTec Group Pharmaceutical CDMO Services Introduction
11.7.4 WuXi AppTec Group Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.7.5 WuXi AppTec Group Recent Development
11.8 Strides Pharma Science Limited
11.8.1 Strides Pharma Science Limited Company Detail
11.8.2 Strides Pharma Science Limited Business Overview
11.8.3 Strides Pharma Science Limited Pharmaceutical CDMO Services Introduction
11.8.4 Strides Pharma Science Limited Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.8.5 Strides Pharma Science Limited Recent Development
11.9 Piramal Pharma Solutions
11.9.1 Piramal Pharma Solutions Company Detail
11.9.2 Piramal Pharma Solutions Business Overview
11.9.3 Piramal Pharma Solutions Pharmaceutical CDMO Services Introduction
11.9.4 Piramal Pharma Solutions Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.9.5 Piramal Pharma Solutions Recent Development
11.10 Siegfried Ltd
11.10.1 Siegfried Ltd Company Detail
11.10.2 Siegfried Ltd Business Overview
11.10.3 Siegfried Ltd Pharmaceutical CDMO Services Introduction
11.10.4 Siegfried Ltd Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.10.5 Siegfried Ltd Recent Development
11.11 Fareva Group
11.11.1 Fareva Group Company Detail
11.11.2 Fareva Group Business Overview
11.11.3 Fareva Group Pharmaceutical CDMO Services Introduction
11.11.4 Fareva Group Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.11.5 Fareva Group Recent Development
11.12 FAMAR Health Care Services
11.12.1 FAMAR Health Care Services Company Detail
11.12.2 FAMAR Health Care Services Business Overview
11.12.3 FAMAR Health Care Services Pharmaceutical CDMO Services Introduction
11.12.4 FAMAR Health Care Services Revenue in Pharmaceutical CDMO Services Business (2019-2024)
11.12.5 FAMAR Health Care Services Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
